Autoimmune and Metabolic Diseases and the Risk of Early-Onset Colorectal Cancer, a Nationwide Nested Case-Control Study

Cancers (Basel). 2023 Jan 22;15(3):688. doi: 10.3390/cancers15030688.

Abstract

Incidence of early-onset (<50 years) colorectal cancer (EOCRC) is increasing in developed countries. The aim was to investigate autoimmune and metabolic conditions as risk factors for EOCRC. In a nationwide nested case-control study, we included all EOCRC cases in Sweden diagnosed during 2007-2016, together with controls, matched for birth year, sex, and county. Information on exposure of autoimmune or metabolic disease was collected from the National Patient Register and Prescribed Drugs Registry. Hazard ratios (HR) as measures of the association between EOCRC and the exposures were estimated using conditional logistic regression. In total, 2626 EOCRC patients and 15,756 controls were included. A history of metabolic disease nearly doubled the incidence hazard of EOCRC (HR 1.82, 95% CI 1.66-1.99). A sixfold increased incidence hazard of EOCRC (HR 5.98, 95% CI 4.78-7.48) was seen in those with inflammatory bowel disease (IBD), but the risk increment decreased in presence of concomitant metabolic disease (HR 3.65, 95% CI 2.57-5.19). Non-IBD autoimmune disease was not statistically significantly associated with EOCRC. IBD and metabolic disease are risk factors for EOCRC and should be considered in screening guidelines.

Keywords: autoimmune disease; diabetes mellitus; early-onset colorectal cancer; hyperlipidemia; hypertension; inflammatory bowel disease; metabolic disease; obesity; risk factors.

Grants and funding

The study was supported financially by the Swedish Research Council, the Swedish Cancer Society, and the Stockholm Cancer Society, and supported by grants provided by the Medical Research Council of Southeast Sweden, Region Stockholm (ALF project), as well as the Bengt Ihre Foundation and Mag-Tarmfonden.